Clinical trials: Urologic Diseases
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for…
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3
- Trial name
- NCT03518320
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Taris Biomedical LLC
Kidney Disease, Diabetes Mellitus
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage…
- Conditions
- Kidney Disease, Diabetes Mellitus, Anemia
- Trial name
- NCT00093015
- Testing
- darbepoetin alfa
- Volunteers
- 4,038 people
- Sponsor
- Amgen
Urinary Incontinence, Stress
Perineal Ultrasound in Men Before and After Radical Prostatectomy
Prospective study to evaluate a new technique. Comparison of perineal sonography in men before and after radical prostatectomy and in incontinent men after radical prostatectomy before and after operative treatment with male…
- Trial name
- NCT03037008
- Testing
- Perineal Sonography
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Kantonsspital Winterthur KSW
Urologic Neoplasm
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.
- Trial name
- NCT00350025
- Testing
- Cetuximab, Paclitaxel
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Fox Chase Cancer Center
Renal Cell Carcinoma
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
Cancer immunotherapy has been largely adopted in oncology patient management in the last decade. The deep and long responses to immunotherapy have accelerated the approval of these drugs across multiple disease sites.
- Trial name
- PERFORM (NCT04163289)
- Testing
- Fecal Microbiota Transplantation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Renal Failure, Kidney Donors
BOne Dysfunction in Donor NEphrectomieS
Most dialysis patients die from vascular disease, which is statistically associated with changes related to chronic kidney disease associated mineral bone disorder (CKD-MBD)3-9.
- Trial name
- BONES (NCT04674397)
- Testing
- Radioisotope GFR test
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Manchester University NHS Foundation Trust
Urinary Incontinence, Stress
Duloxetine Stress Urinary Incontinence Efficacy and Safety Study
Study F1J-MC-SBBU will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.
- Trial name
- NCT00475397
- Testing
- Duloxetine
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma, Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
- Trial name
- NCT01482520
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Sequential Therapy in Metastatic Renal Cell Carinoma
Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
- Trial name
- BERAT (NCT01731158)
- Testing
- Avastin in combination with Roferon-A, Afinitor, TKI: Sutent, Nexavar or Votrient
- Where
- 13 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Renal Disease, Adherence, Treatment
The Effect of Motivational Interviewing and Education Based on Watson's Theory of Human Caring in Hemodialysis
Motivational interviewing and education based on Watson's Theory of Human Caring have an effect on increasing adherence to fluid intake in individuals receiving hemodialysis treatment.
- Conditions
- Renal Disease, Adherence, Treatment, Quality of Life, Satisfaction, Patient
- Trial name
- NCT04174638
- Testing
- Motivational Interviewing and Education Based on Watson's Theory of Human Caring
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Urinary Incontinence, Urge
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt
The ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed…
- Trial name
- ARTISAN-SNM (NCT03327948)
- Testing
- Axonics Sacral Neuromodulation System (SNM) System
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 129 people
- Sponsor
- Axonics, Inc.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma
- Trial name
- NCT04544748
- Testing
- GNR-051
- Where
- 12 sites in Russia
- Volunteers
- 48 people
- Sponsor
- AO GENERIUM
Chronic Kidney Disease
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704678)
- Testing
- SBR759, Sevelamer HCl
- Where
- 15 sites in Japan, Taiwan
- Volunteers
- 203 people
- Sponsor
- Novartis Pharmaceuticals
Fatigue; Hemodialysis; Chronic Kidney Disease; Quality of Life
Effectiveness of Slow Back Stroke Massage and Murrotal Quran on Fatigue and Quality of Life of Patients Undergoing Haemodialysis
The study aimed to investigate the effectiveness of slow back stroke massage and murrotal Quran on fatigue and quality of life on patients undergoing hemodialysis.
- Trial name
- EMQ (NCT05183815)
- Testing
- slow stroke massage and murrotal quran
- Volunteers
- 30 people
- Sponsor
- Universitas Muhammadiyah Yogyakarta
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00096525
- Testing
- lenalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
End-Stage Kidney Disease
Biological Determinants of Peritoneal Dialysis
Peritoneal Dialysis (PD) is a technique for treating kidney failure where fluid is instilled into the body's peritoneal cavity. Fluid and solutes travel across the peritoneal membrane, and the function of this membrane is…
- Trial name
- Bio-PD (NCT02694068)
- Testing
- Peritoneal Equilibrium Test, 4 hour dwell of 2.5/4.25% dextrose solution
- Where
- United States
- Volunteers
- 4,865 people
- Sponsor
- University of Washington
Chronic Kidney Diseases, Renal Disease
Pain Relief Intervention of Meditation in Renal Disease (PRIMER)
Kidney Disease subjects will be recruited to take part of a mindfulness-based stress reduction intervention for 8-10 sessions. All subjects will complete a baseline interview, one follow-up at 3 months and the close out interview…
- Conditions
- Chronic Kidney Diseases, Renal Disease, Chronic Kidney Failure, End Stage Renal Disease
- Trial name
- PRIMER (NCT03161197)
- Testing
- Mindfulness-Based Stress Reduction
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Urinary Bladder, Neurogenic
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
The proposed study is a randomized, double blind placebo controlled multicenter study to determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction.
- Trial name
- NCT02044510
- Testing
- Mirabegron
- Where
- 5 sites in Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.